Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

0
102

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid tumours

Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving “First Patient First Visit[1]” in Phase 1B. The first dose of ETC-159 has been administered to patients in this new phase of clinical testing, which for the first time, will look at efficacy in addition to assessing the safety of ETC-159 in treating different types of cancers.

Scientists from the Experimental Drug Development Centre, A*STAR, preparing ETC-159 clinical samples for real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) which amplifies the genetic material. (Photo credit: A*STAR)

Scientists from the Experimental Drug Development Centre, A*STAR, using centrifuges to bring ETC-159 clinical sample reactions down. (Photo credit: A*STAR)

Scientists from the Experimental Drug Development Centre, A*STAR, performing real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) to amplify the genetic material from ETC-159 clinical samples. From L-R: Ms Sylvia Gan, Senior Research Manager; Ms Nurul Rozaini, Research Associate (Photo credit: A*STAR)

LEAVE A REPLY